511 related articles for article (PubMed ID: 25702326)
1. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.
Zhou Y; Shi D; Miao J; Wu H; Chen J; Zhou X; Hu D; Zhao C; Deng W; Xie C
Sci Rep; 2017 Mar; 7():43627. PubMed ID: 28256540
[TBL] [Abstract][Full Text] [Related]
3. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
[TBL] [Abstract][Full Text] [Related]
4. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
5. PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial.
Cao C; Wei Q; Tang X; Jia Y; Sun X; Li W; Hu Q; Chen X
Head Neck; 2019 May; 41(5):1427-1433. PubMed ID: 30582240
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
Cao Y; Chan KI; Xiao G; Chen Y; Qiu X; Hao H; Mak SC; Lin T
BMC Cancer; 2019 Oct; 19(1):1022. PubMed ID: 31664962
[TBL] [Abstract][Full Text] [Related]
7. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
8. Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.
Lee VH; Lo AW; Leung CY; Shek WH; Kwong DL; Lam KO; Tong CC; Sze CK; Leung TW
PLoS One; 2016; 11(6):e0157969. PubMed ID: 27341634
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
10. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.
Feng C; Zhang Y; Huang J; Zheng Q; Yang Y; Xu B
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):239-244. PubMed ID: 32205739
[TBL] [Abstract][Full Text] [Related]
12. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H
J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
14. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
Chan OS; Kowanetz M; Ng WT; Koeppen H; Chan LK; Yeung RM; Wu H; Amler L; Mancao C
Oral Oncol; 2017 Apr; 67():52-60. PubMed ID: 28351581
[TBL] [Abstract][Full Text] [Related]
15. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma.
Tang Y; He Y; Shi L; Yang L; Wang J; Lian Y; Fan C; Zhang P; Guo C; Zhang S; Gong Z; Li X; Xiong F; Li X; Li Y; Li G; Xiong W; Zeng Z
Oncotarget; 2017 Jun; 8(24):39001-39011. PubMed ID: 28380458
[TBL] [Abstract][Full Text] [Related]
18. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.
Ono T; Azuma K; Kawahara A; Sasada T; Matsuo N; Kakuma T; Kamimura H; Maeda R; Hattori C; On K; Nagata K; Sato F; Chitose SI; Shin B; Aso T; Akiba J; Umeno H
Head Neck; 2018 Sep; 40(9):2007-2019. PubMed ID: 29756253
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
Hu B; Sun M; Wang Z; Zheng Y; Cai W; Shi HH; Zhuang Y; Lin Q
Clin Chem; 2020 Sep; 66(9):1219-1227. PubMed ID: 32870999
[TBL] [Abstract][Full Text] [Related]
20. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
